69.06
11.47%
-8.95
Pre-market:
70.94
1.88
+2.72%
Viking Therapeutics Inc stock is currently priced at $69.06, with a 24-hour trading volume of 7.46M.
It has seen a -11.47% decreased in the last 24 hours and a +1.63% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $76.86 pivot point. If it approaches the $66.65 support level, significant changes may occur.
Previous Close:
$78.01
Open:
$76.26
24h Volume:
7.46M
Market Cap:
$7.62B
Revenue:
-
Net Income/Loss:
$-93.72M
P/E Ratio:
-74.26
EPS:
-0.93
Net Cash Flow:
$-54.87M
1W Performance:
-13.89%
1M Performance:
+1.63%
6M Performance:
+555.84%
1Y Performance:
+180.22%
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
12340 El Camino Real, Suite 250, San Diego, CA
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-31-23 | Resumed | ROTH MKM | Buy |
Mar-28-23 | Reiterated | Maxim Group | Buy |
Mar-17-23 | Initiated | Stifel | Buy |
Jul-29-21 | Resumed | BTIG Research | Buy |
May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
May-05-20 | Initiated | Chardan Capital Markets | Buy |
May-01-20 | Initiated | BTIG Research | Buy |
Jul-16-19 | Initiated | Oppenheimer | Outperform |
Jun-25-19 | Initiated | Stifel | Buy |
Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Mar-14-19 | Reiterated | Maxim Group | Buy |
Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
Dec-12-18 | Initiated | B. Riley FBR | Buy |
Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
Sep-18-18 | Reiterated | Maxim Group | Buy |
Sep-18-18 | Reiterated | Raymond James | Outperform |
Jul-20-18 | Initiated | SunTrust | Buy |
Jun-28-18 | Initiated | Raymond James | Outperform |
Jun-01-18 | Reiterated | Laidlaw | Buy |
May-31-18 | Reiterated | Maxim Group | Buy |
Mar-26-18 | Resumed | H.C. Wainwright | Buy |
Nov-28-17 | Reiterated | Maxim Group | Buy |
Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock's a buy. - MSN
MSN
Viking Therapeutics (NASDAQ:VKTX) Raised to "Strong-Buy" at Raymond James - MarketBeat
MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down to $78.01 - MarketBeat
MarketBeat
Truist maintains $120 target on Viking Therapeutics stock By Investing.com - Investing.com
Investing.com
Viking stock falls after Roche's obesity data (NASDAQ:VKTX) - Seeking Alpha
Seeking Alpha
Viking stock falls after Roche's obesity data (NASDAQ:VKTX) - Seeking Alpha
Seeking Alpha
Viking Therapeutics Inc Stock (VKTX) Financials Data
Viking Therapeutics Inc (VKTX) Net Income 2024
VKTX net income (TTM) was -$93.72 million for the quarter ending March 31, 2024, a -29.64% decrease year-over-year.
Viking Therapeutics Inc (VKTX) Cash Flow 2024
VKTX recorded a free cash flow (TTM) of -$54.87 million for the quarter ending March 31, 2024, a +12.23% increase year-over-year.
Viking Therapeutics Inc (VKTX) Earnings per Share 2024
VKTX earnings per share (TTM) was -$0.93 for the quarter ending March 31, 2024, a +2.11% growth year-over-year.
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):